AQX-1125: Completed Phase II enrollment

Aquinox completed enrollment of about 50 patients in the double-blind, placebo-controlled, Canadian Phase II KINSHIP trial to evaluate once-daily oral AQX-1125 for 12 weeks. Top-line data are expected...